$FTLF
FITLIFE BRANDS, INC. Stock $ftlf

$ftlf Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000143774924016353 Filed on May 14, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$16.93M	$16.55M	$10.74M
YoY Change	14.7%	54.12%	44.04%
Cost Of Revenue	$9.350M	$9.262M	$6.330M
YoY Change	6.31%	46.32%	51.33%
Gross Profit	$7.580M	$7.287M	$4.408M
YoY Change	27.07%	65.31%	34.72%
Gross Profit Margin	44.77%	44.03%	41.05%
Selling, General & Admin	$2.528M	$3.736M	$2.344M
YoY Change	-22.05%	59.39%	41.03%
% of Gross Profit	33.35%	51.27%	53.18%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$16.00K	$36.00K	$19.00K
YoY Change	23.08%	89.47%	35.71%
% of Gross Profit	0.21%	0.49%	0.43%
Operating Expenses	$3.905M	$3.906M	$3.735M
YoY Change	15.5%	4.58%	122.85%
Operating Profit	$3.675M	$3.381M	$673.0K
YoY Change	42.22%	402.38%	-57.83%
Interest Expense	-$318.0K	$414.0K	$98.00K
YoY Change	-226.69%	322.45%	1300.0%
% of Operating Profit	-8.65%	12.24%	14.56%
Other Income/Expense, Net	-$318.0K	-$414.0K	-$96.00K
YoY Change	-2220.0%	331.25%	-1471.43%
Pretax Income	$3.357M	$2.967M	$577.0K
YoY Change	29.17%	414.21%	-64.0%
Income Tax	$729.0K	$807.0K	$421.0K
% Of Pretax Income	21.72%	27.2%	72.96%
Net Earnings	$2.628M	$2.160M	$156.0K
YoY Change	33.81%	1284.62%	-87.91%
Net Earnings / Revenue	15.52%	13.05%	1.45%
Basic Earnings Per Share	$0.57	$0.47	$0.03
Diluted Earnings Per Share	$0.53	$0.43	$0.03
COMMON SHARES
Basic Shares Outstanding	4.598M	4.598M	4.446M
Diluted Shares Outstanding	4.950M	5.030M	4.935M

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.680M	$2.540M	$7.977M
YoY Change	-58.57%	-68.16%	-27.88%
Cash & Equivalents	$3.735M	$3.290M	$8.927M
Short-Term Investments
Other Short-Term Assets	$966.0K	$1.201M	$2.397M
YoY Change	-36.45%	-49.9%	1352.73%
Inventory	$9.779M	$8.869M	$8.791M
Prepaid Expenses
Receivables	$2.498M	$2.269M	$2.045M
Other Receivables	$111.0K	$113.0K	$0.00
Total Short-Term Assets	$17.03M	$14.99M	$21.21M
YoY Change	-24.11%	-29.32%	6.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$106.0K	$121.0K	$118.0K
YoY Change	-34.57%	2.54%	100.0%
Goodwill	$13.11M	$13.34M	$10.79M
YoY Change	-3.33%	23.67%	2913.13%
Intangibles	$26.31M	$26.33M	$7.769M
YoY Change	230.63%	238.85%	4192.27%
Long-Term Investments
YoY Change
Other Assets	$682.0K	$612.0K	$1.596M
YoY Change	-49.26%	-61.65%	-41.67%
Total Long-Term Assets	$40.28M	$40.49M	$20.46M
YoY Change	73.71%	97.97%	486.94%
TOTAL ASSETS
Total Short-Term Assets	$17.03M	$14.99M	$21.21M
Total Long-Term Assets	$40.28M	$40.49M	$20.46M
Total Assets	$57.31M	$55.49M	$41.67M
YoY Change	25.59%	33.17%	77.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.309M	$3.978M	$4.881M
YoY Change	20.67%	-18.5%	43.1%
Accrued Expenses	$1.140M	$1.470M	$1.987M
YoY Change	-63.89%	-26.02%	250.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.500M	$4.500M	$2.500M
YoY Change	80.0%	80.0%
Total Short-Term Liabilities	$12.32M	$11.83M	$9.949M
YoY Change	25.53%	18.89%	114.79%
LONG-TERM LIABILITIES
Long-Term Debt	$10.78M	$11.89M	$10.00M
YoY Change	14.97%	18.94%
Other Long-Term Liabilities	$25.00K	$34.00K	$108.0K
YoY Change	-70.59%	-68.52%	20.0%
Total Long-Term Liabilities	$10.78M	$11.89M	$10.00M
YoY Change	14.97%	18.94%	11011.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.32M	$11.83M	$9.949M
Total Long-Term Liabilities	$10.78M	$11.89M	$10.00M
Total Liabilities	$25.46M	$26.11M	$20.06M
YoY Change	16.85%	30.17%	324.76%
SHAREHOLDERS EQUITY
Retained Earnings	$1.371M	-$1.257M	-$8.557M
YoY Change	-120.79%	-85.31%	-27.8%
Common Stock	$46.00K	$46.00K	$44.00K
YoY Change	4.55%	4.55%	-4.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$31.86M	$29.38M	$21.61M
YoY Change
Total Liabilities & Shareholders Equity	$57.31M	$55.49M	$41.67M
YoY Change	25.59%	33.17%	77.34%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	$2.628M	$2.160M	$156.0K
YoY Change	33.81%	1284.62%	-87.91%
Depreciation, Depletion And Amortization	$16.00K	$36.00K	$19.00K
YoY Change	23.08%	89.47%	35.71%
Cash From Operating Activities	$1.570M	$5.036M	$232.0K
YoY Change	0.51%	2070.69%	-79.54%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$10.00K	$0.00
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$17.10M
YoY Change		-100.0%
Cash From Investing Activities	$0.00	-$10.00K	-$17.10M
YoY Change	-100.0%	-99.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$3.625M	$0.00
YoY Change
Cash From Financing Activities	-1.125M	-$3.625M	$12.50M
YoY Change	80.0%	-129.0%	43003.45%
NET CHANGE
Cash From Operating Activities	1.570M	$5.036M	$232.0K
Cash From Investing Activities	0.000	-$10.00K	-$17.10M
Cash From Financing Activities	-1.125M	-$3.625M	$12.50M
Net Change In Cash	445.0K	$1.392M	-$4.350M
YoY Change	-49.6%	-132.0%	-474.03%
FREE CASH FLOW
Cash From Operating Activities	$1.570M	$5.036M	$232.0K
Capital Expenditures	$0.00	$10.00K	$0.00
Free Cash Flow	$1.570M	$5.026M	$232.0K
YoY Change	4.11%	2066.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001374328
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q1	ftlf	Shares Forfeited During Period Value SharesForfeitedDuringPeriodValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Cash Cash	1139000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	759000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	17000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2046000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	162000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	9091000	usd
CY2023Q4	ftlf	Sales Taxes Receivable SalesTaxesReceivable	1019000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	639000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	14693000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	137000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	121000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	113000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26309000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	13294000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	792000	usd
CY2023Q4	us-gaap	Assets Assets	55346000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3978000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3261000	usd
CY2024Q1	ftlf	Accrued Expense And Other Liabilities Current AccruedExpenseAndOtherLiabilitiesCurrent	1397000	usd
CY2023Q4	ftlf	Accrued Expense And Other Liabilities Current AccruedExpenseAndOtherLiabilitiesCurrent	1026000	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1356000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	892000	usd
CY2024Q1	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	524000	usd
CY2023Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	571000	usd
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	4500000	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	4500000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	73000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	87000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11828000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10337000	usd
CY2024Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	11894000	usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	15509000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2353000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2413000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	26109000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	28310000	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4598000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4598000
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	46000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	46000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30801000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30699000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1257000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3417000	usd
CY2024Q1	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	-213000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	36000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-14000	usd
CY2024Q1	us-gaap	Inventory Write Down InventoryWriteDown	-23000	usd
CY2023Q4	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	-292000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	29377000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	27036000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55486000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55346000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	7287000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3736000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2344000	usd
CY2024Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	134000	usd
CY2023Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	1372000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	36000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	19000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	3906000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	3735000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3381000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	673000	usd
CY2024Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	5000	usd
CY2023Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	84000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	414000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	98000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-82000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-414000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-96000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2967000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	577000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	807000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	421000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	2160000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	156000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.47
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.43
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4598000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4483000
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5030000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4935000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	2160000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	156000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	79000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2239000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	156000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	27036000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	102000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	79000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	2160000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	29377000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21388000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	2000	usd
CY2024Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	102000	usd
CY2023Q1	ftlf	Shares Surrendered By Former Employee SharesSurrenderedByFormerEmployee	0	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	42000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	22000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	156000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	21608000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	2160000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	156000	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	42000	usd
CY2024Q1	ftlf	Amortization Of Deferred Finance Costs AmortizationOfDeferredFinanceCosts	10000	usd
CY2023Q1	ftlf	Amortization Of Deferred Finance Costs AmortizationOfDeferredFinanceCosts	1000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	242000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	917000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-218000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1501000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-180000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-251000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1067000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	44000	usd
CY2024Q1	ftlf	Operating Lease Rightofuse Asset Net Of Amortization And Lease Liability OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability	-21000	usd
CY2023Q1	ftlf	Operating Lease Rightofuse Asset Net Of Amortization And Lease Liability OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability	-16000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	727000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1045000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-30000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-16000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	856000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	289000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-47000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-9000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5036000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	232000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2024Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	-0	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	17099000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17099000	usd
CY2024Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3625000	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	-0	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	12500000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3625000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12500000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-9000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1392000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4350000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1898000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13277000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3290000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8927000	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE 1 - DESCRIPTION OF BUSINESS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">FitLife Brands, Inc. (the “<i>Company</i>”) is a provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, “<i>NDS Products</i>”); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the "<i>iSatori Products</i>"); (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the “<i>MRC Products</i>"); and (iv) MusclePharm.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (“<i>GNC</i>”) stores located both domestically and internationally and, with the launch of Metis Nutrition, through corporate GNC stores in the United States. The iSatori Products are sold through approximately 16,000 retail locations, which include specialty, mass, and online. The Company distributes the MRC Products primarily online. MusclePharm’s products are sold to both wholesale customers as well as online directly to the end consumer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com. The Company’s common stock, par value $0.01 per share (“<i>Common Stock</i>”), trades under the symbol “FTLF” on the Nasdaq Capital Market.</p>
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4500000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.272	pure
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.73	pure
CY2024Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE 2 - BASIS OF PRESENTATION</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation are included. Operating results for the three-month period ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. Although management of the Company believes the disclosures presented herein are adequate and not misleading, these interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the footnotes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (the “<i>SEC</i>”) on March 29, 2024.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p>
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Use of Estimates and Assumptions</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.</p>
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	2160000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	156000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4598000
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Customer and Vendor Concentration</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net sales to GNC during the three-month periods ended March 31, 2024 and 2023 represent 25% and 49% of total net revenue, respectively. Gross accounts receivable attributable to GNC as of March 31, 2024 and December 31, 2023 represent 28% and 30% of the Company’s total accounts receivable balance, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the three months ended March 31, 2024<i>,</i> there were two vendors who accounted for 42% and 27% of the Company's inventory-related purchases. For the quarter ended March 31, 2023<i>,</i> there were <span style="-sec-ix-hidden:c362">two</span> vendors who accounted for 49% and 18% of the Company's inventory-related purchases. As of March 31, 2024 and December 31, 2023, there was <span style="-sec-ix-hidden:c369"><span style="-sec-ix-hidden:c370">one</span></span> vendor who accounted for 62% and 51% of the Company's consolidated accounts payable, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4483000
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	432000
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	452000
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5030000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4935000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.47
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.43
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	139000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	162000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8125000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8292000	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	883000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	961000	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	139000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	162000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	8869000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	9091000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	965000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	951000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	844000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	814000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	121000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	137000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	26000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	9000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11894000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15509000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	3375000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	4500000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2625000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	1500000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	16500000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4598000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	160000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	468000	usd
CY2023Q1	ftlf	Shares Forfeited During Period Shares SharesForfeitedDuringPeriodShares	61200
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	484000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.82
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y6M
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	-0
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	484000
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.82
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y3M18D
CY2024Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	484000
CY2024Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P4Y3M18D
CY2024Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	6.82
CY2024Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	401000
CY2024Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	4.31
CY2024Q1	us-gaap	Share Price SharePrice	23.81
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8228000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	638000	usd

Files In Submission

Name	View Source	Status
0001437749-24-016353-index-headers.html	Edgar Link	pending
0001437749-24-016353-index.html	Edgar Link	pending
0001437749-24-016353.txt	Edgar Link	pending
0001437749-24-016353-xbrl.zip	Edgar Link	pending
ex_664736.htm	Edgar Link	pending
ex_664737.htm	Edgar Link	pending
ex_664738.htm	Edgar Link	pending
ex_664739.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ftlf-20240331.xsd	Edgar Link	pending
ftlf20240331_10q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
ftlf-20240331_cal.xml	Edgar Link	unprocessable
ftlf-20240331_def.xml	Edgar Link	unprocessable
ftlf-20240331_lab.xml	Edgar Link	unprocessable
ftlf20240331_10q_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ftlf-20240331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FTLF
FITLIFE BRANDS, INC. Stock $ftlf

2024 Q2 Form 10-Q Financial Statement

#000143774924016353 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FTLF FITLIFE BRANDS, INC. Stock $ftlf

2024 Q2 Form 10-Q Financial Statement

#000143774924016353 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FTLF
FITLIFE BRANDS, INC. Stock $ftlf